Last reviewed · How we verify
NCT05564923
CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab
trial testing there is no intervention in Nivolumab Related Toxicity in 100 participants. Status unknown.
17 June 2023
Quick facts
| Lead sponsor | Namik Kemal University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 2 September 2022 |
| Primary completion | 17 June 2023 |
| Estimated completion | 17 August 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- there is no intervention — full drug profile →
Conditions studied
- Nivolumab Related Toxicity — all drugs for Nivolumab Related Toxicity →
Sponsor
Namik Kemal University
Who can join
60 and older, any sex, with Nivolumab Related Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Geriatric 8 (G8), Vulnerable Elders Survey (VES-13), and Cancer and Aging Research Group (CARG) questionnaires are among the main tests whose purpose is to predict the risk of chemotherapy-induced toxicity (CRT) and allow treatment. Investigators aimed to investigate the effect of using the G8, VES13, and CARG scales in the geriatric age group in cancer patients receiving nivolumab treatment in predicting side effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05564923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of there is no intervention
Trials testing the same drug.
- NCT07396467 — Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis · active not recruiting
- NCT05912413 — Predicton of Sepsis Recovery Performance Subtypes Pilot Study · recruiting
- NCT07021326 — Phase Angle and TyG Index as Markers of Glycaemic Control, Adiposity and Cardiovascular Risk in T1D Adolescents · completed
- NCT04212143 — Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients · active not recruiting
- NCT06369805 — EVALUATION OF BLOOD BIOMARKER-BASED DIAGNOSTIC AID IN OUTPATIENTS SUFFERING FROM DEPRESSION · completed
Other Namik Kemal University trials
Trials by the same sponsor.
- NCT07349862 — Flipped Learning in Nursing Education · NA · enrolling by invitation
- NCT07348549 — Gagne Learning Model in Nursing Education · NA · enrolling by invitation
- NCT07467304 — Nursing Education Provided After Cesarean Section Surgery. · NA · enrolling by invitation
- NCT05671484 — TFPB vs QLB III in Infra-umbilical Pediatric Surgeries · NA · completed
- NCT05928845 — Sternocleidomastoid Thickness in Sarcopenia · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05564923 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Namik Kemal University
- Last refreshed: 4 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05564923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing